Lilly's Gemzar appeal fails to get Supreme Court hearing

The U.S. Supreme Court has turned away Eli Lilly's appeal in a dispute over the company's patent on the cancer drug Gemzar, leaving intact a lower-court ruling that opened the door to generic competition. Report